Press Releases

Keep up with our latest news

Frelii, Inc. Opens its First Subsidiary in Canada

07-16-19

LEHI, Utah–(BUSINESS WIRE)–Frelii, Inc. (OTC PINK: FRLI) (“Frelii” or “the Company”) has opened a new wholly owned subsidiary, Frelii Canada Inc. in Mississauga, Ontario, Canada, making it the Company’s first subsidiary supporting the Lehi, Utah headquarters. Frelii Canada will be led by Sandy Uppal, Chief Administrative Officer at Frelii and supported by Yvan Aubin, Executive Vice President of Finance at Frelii. 

“The establishment of this subsidiary will enable Frelii to manage operational activities and better serve our growing Canadian customer base,” Uppal said. “Frelii technology, including its artificial intelligence (AI) and whole-genome DNA analysis is highly sought after in the Canadian marketplace, particularly as it delivers solutions and insights and address challenges in the recreational and medical cannabis industries.” (Continue Reading)

 

Using AI and Big DNA Data to Advance Drug Development and Delivery

06-27-19

Artificial intelligence is rapidly advancing the capabilities and possibilities of whole genome sequencing. Through the use of this advanced technology, the pharmaceutical industry can deliver precise dosing on a scale and at a level of accuracy never before seen. AI can provide personalized predictions to determine likely physical and psychological effects of drug interaction in an individual body. While big data is increasing our access to questions, it is also creating new discoveries and new questions that have yet to be answered. One thing is for sure, AI, big data, and whole genome sequencing will impact the cost of drug development and delivery. This webcast explores these topics in depth. (View Webinar)

 

PBMI Hosts Live Webinar with CEO of Frelii, Inc. on the Future of AI, Big DNA Data and Precision Dosing

06-19-19

LEHI, Utah–(BUSINESS WIRE)–Frelii, Inc. (OTC PINK: FRLI) (“Frelii” or “the Company”) today announced that Ian Jenkins, CEO of Frelii, will present a live webinar on “Using AI and Big DNA Data to Advance Drug Development and Delivery.” The free webinar, hosted by the Pharmacy Benefit Management Institute (PBMI), will take place on Thursday, June 27, 2019 at 1:30 p.m. Eastern Time. Register for this highly anticipated event here. (Continue Reading)

 

Frelii, Inc. Inks Agreement with Orn Health Inc. to Support Healthcare Franchisee Partners Incorporating Pharmacogentics Into Patient Treatment

06-10-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTC PINK: FRLI) (“Frelii” or “the Company”) today announced the details of its recent agreement with Orn Health Inc. (Orn), a medical services provider, to license the Frelii exome and whole genome sequencing and artificial intelligence (AI) technology for use with new franchisee partners in their own medical practices for enhancing patient treatment resources. (Continue Reading)

 

Frelii Issues Letter to Shareholders

05-29-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) today announced it has issued a press release with the following letter to shareholders.

Dear fellow shareholders,

The last several months have been very eventful for Frelii and I wanted to take the opportunity to bring you up to date on the excellent progress we have been making. We recently posted our quarterly financial statement, which can be viewed at www.frelii.com. We’ve entered into a relationship with our first customer, and we’ve continue to gain positive interest from legitimate media and investors.

In spite of many good announcements and positive milestones achieved, I also want to address a concern regarding our common stock. (Continue Reading)

 

Frelii Expands Executive Team with Industry Veterans

05-22-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) today announced it has added two key chief officers and an EVP to enhance and strengthen its leadership team. Board Director, Leslie M. Norris has been named Chief Operations Officer and Sandeep Uppal, MBA, named as Chief Administrative Officer. Yvan Aubin, CPA, CA to serve as Executive Vice President of Finance. (Continue Reading)

 

Frelii Files Quarterly Report on Form 10-Q

05-20-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) today announced that on May 20, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. The filing is available on Frelii’s website at https://frelii.com/investors/.

 

Optivida Health Contracts with Frelii, Inc for DNA Sequencing Services to Maximize Hemp Extract and CBD Use, Alignment & Understanding by Customers

05-01-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that it has signed a contract and licensing agreement with Optivida Health (Optivida), one of the nation’s leaders in advanced hemp extract for the consumer market. Optivida will leverage Frelii’s proprietary DNA Kit Packages™ to ensure Optivida customers can realize the optimal benefits of which specific Optivida products best suit their unique DNA profile. (Continue Reading)

 

Frelii Enters Strategic Agreement to Advance Cutting-edge Genomic Science and Applications

03-20-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that it has signed a Memorandum of Understanding (MOU) with NewPath Health Care Solutions, Inc. of Ontario, Canada; Mercator Biologic, Inc. of Centerville, Utah; and True DNA Story, LLC of Centerville, Utah. The purpose of the MOU is to strategically explore the full capabilities of each company to identify synergies and opportunities in order to leverage the unique skillsets of the collective. (Continue Reading)

Frelii Appoints Two New Members to its Scientific Advisory Board

02-14-19

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that it has appointed two renowned physicians, Anthony R. Torres, M.D. and Susan H. Morelli M.D., to its Scientific Advisory Board. (Continue Reading)

 

Frelii Speaks with Potential Partners at CES about the Future of AI in DNA Sequencing and Analysis

01-11-19

LAS VEGAS–(BUSINESS WIRE)–SPECIAL TO CES—Executives from Frelii Inc. (OTCQB: FRLI) met with potential partners and prospects from industries including medical cannabis, precision medicine, consumer wellness, insurance and hospital systems during the CES conference in Las Vegas, Nevada. The Frelii team discussed recent advancements in artificial intelligence (AI) systems that are fueling an AI-driven revolution in the field of genomics and DNA sequencing. (Continue Reading)

 

Frelii Begins Trading on OTC Venture Market

12-28-18

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that its common shares are now trading on the OTCQB Venture Market (“OTCQB”), a U.S. trading platform operated by OTC Markets Group in New York. The Company will trade under the ticker symbol “FRLI” beginning on December 28, 2018. (Continue Reading)

 

Frelii Appoints Seasoned Expert as New Board Member to Support Growth & Expand Strategic Positioning

12-20-18

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTC Pink: FRLI) (“Frelii” or the “Company”) announced the appointment of Leslie M. Norris to its Board of Directors (the “Board”), effective December 12, 2018. (Continue Reading)

 

Frelii Updates Strategic Roadmap to Target Five Key High Growth Market Segments

12-19-18

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQX: FRLI), today provided a shareholder update on the Company’s strategic roadmap detailing how it will further evolve its proprietary DNA profiling artificial intelligence (AI) to meet the growing demands of targeted market segments, including medical cannabis use analysis, telehealth and precision medicine, life and health insurance, consumer wellness and hospital systems. (Continue Reading)